Caribou Biosciences Brass Face Investor's Clinical Trials Suit

By Sydney Price · March 12, 2025, 7:53 PM EDT

Executives and directors of Caribou Biosciences Inc. have been hit with a shareholder's derivative suit alleging that they overstated the safety and efficacy of Caribou's cell therapy and concealed that the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Allen v. Braunstein et al

Case Number

Court

California Northern

Nature of Suit

Stockholders Suits

Date Filed

March 11, 2025

Recent Articles By Sydney

February 10, 2025
Pharma Co. Misled Investors On Depression Drug, Suit Says
January 22, 2025
Pharma Co. Says Ex-CEO's Alleged Misconduct Is Not Fraud
January 08, 2025
Biotech Co.'s Facility Failures Lost Investors Money, Suit Says
January 02, 2025
Edwards Brass Face Investor Suit Over Heart Valve Sales
December 02, 2024
Investor Alleges Medical Device Co. Misled On FDA Clearance
November 21, 2024
SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'
November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies